Cargando…
Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960037/ https://www.ncbi.nlm.nih.gov/pubmed/30301310 http://dx.doi.org/10.3904/kjim.2018.064 |
_version_ | 1783487702644031488 |
---|---|
author | Lee, In Hee Kang, Byung Woog Kim, Jong Gwang Bae, Woo Kyun Ki, Myung Seo Park, Inkeun Jo, Jae-Cheol Kim, Jin Young Koh, Sung Ae Lee, Kyung Hee Cho, Yoon Young Ryoo, Hun Mo Kwak, Sang Gyu Lee, Jung Lim Lee, Sun Ah |
author_facet | Lee, In Hee Kang, Byung Woog Kim, Jong Gwang Bae, Woo Kyun Ki, Myung Seo Park, Inkeun Jo, Jae-Cheol Kim, Jin Young Koh, Sung Ae Lee, Kyung Hee Cho, Yoon Young Ryoo, Hun Mo Kwak, Sang Gyu Lee, Jung Lim Lee, Sun Ah |
author_sort | Lee, In Hee |
collection | PubMed |
description | BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study applied three prognostic models to Korean non-clear cell RCC patients treated with first-line temsirolimus. METHODS: This study analyzed data for 74 patients with non-clear cell RCC who were treated with temsirolimus as the first-line therapy at eight medical centers between 2011 and 2016. The receiver-operating characteristic (ROC) curves for the different prognostic models were analyzed. RESULTS: Twenty-seven (36.5%), 24 (32.4%), and 44 patients (59.5%) were assigned to the poor prognosis groups of the Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic RCC Database Consortium (IMDC), and Advanced Renal Cell Carcinoma (ARCC) risk stratification models, respectively. All three prognostic models reliably discriminated the risk groups to predict progression-free survival and overall survival (p < 0.001). The area under the ROC curve (AUC) for progression and survival was highest for the ARCC model (0.777; 0.734), followed by the IMDC (0.756; 0.724) and the MSKCC (0.742; 0.712) models. Furthermore, the sensitivity and specificity for predicting progression were highest with the ARCC model (sensitivity 63.6%, specificity 85.7%), followed by the MSKCC (sensitivity 58.2%, specificity 86.5%) and the IMDC models (sensitivity 56.4%, specificity 85.7%). CONCLUSIONS: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival. |
format | Online Article Text |
id | pubmed-6960037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-69600372020-01-22 Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy Lee, In Hee Kang, Byung Woog Kim, Jong Gwang Bae, Woo Kyun Ki, Myung Seo Park, Inkeun Jo, Jae-Cheol Kim, Jin Young Koh, Sung Ae Lee, Kyung Hee Cho, Yoon Young Ryoo, Hun Mo Kwak, Sang Gyu Lee, Jung Lim Lee, Sun Ah Korean J Intern Med Original Article BACKGROUND/AIMS: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study applied three prognostic models to Korean non-clear cell RCC patients treated with first-line temsirolimus. METHODS: This study analyzed data for 74 patients with non-clear cell RCC who were treated with temsirolimus as the first-line therapy at eight medical centers between 2011 and 2016. The receiver-operating characteristic (ROC) curves for the different prognostic models were analyzed. RESULTS: Twenty-seven (36.5%), 24 (32.4%), and 44 patients (59.5%) were assigned to the poor prognosis groups of the Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic RCC Database Consortium (IMDC), and Advanced Renal Cell Carcinoma (ARCC) risk stratification models, respectively. All three prognostic models reliably discriminated the risk groups to predict progression-free survival and overall survival (p < 0.001). The area under the ROC curve (AUC) for progression and survival was highest for the ARCC model (0.777; 0.734), followed by the IMDC (0.756; 0.724) and the MSKCC (0.742; 0.712) models. Furthermore, the sensitivity and specificity for predicting progression were highest with the ARCC model (sensitivity 63.6%, specificity 85.7%), followed by the MSKCC (sensitivity 58.2%, specificity 86.5%) and the IMDC models (sensitivity 56.4%, specificity 85.7%). CONCLUSIONS: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival. The Korean Association of Internal Medicine 2020-01 2018-10-12 /pmc/articles/PMC6960037/ /pubmed/30301310 http://dx.doi.org/10.3904/kjim.2018.064 Text en Copyright © 2020 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, In Hee Kang, Byung Woog Kim, Jong Gwang Bae, Woo Kyun Ki, Myung Seo Park, Inkeun Jo, Jae-Cheol Kim, Jin Young Koh, Sung Ae Lee, Kyung Hee Cho, Yoon Young Ryoo, Hun Mo Kwak, Sang Gyu Lee, Jung Lim Lee, Sun Ah Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title_full | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title_fullStr | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title_full_unstemmed | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title_short | Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
title_sort | comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960037/ https://www.ncbi.nlm.nih.gov/pubmed/30301310 http://dx.doi.org/10.3904/kjim.2018.064 |
work_keys_str_mv | AT leeinhee comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kangbyungwoog comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kimjonggwang comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT baewookyun comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kimyungseo comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT parkinkeun comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT jojaecheol comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kimjinyoung comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kohsungae comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT leekyunghee comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT choyoonyoung comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT ryoohunmo comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT kwaksanggyu comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT leejunglim comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy AT leesunah comparisonofthreeriskstratificationmodelsfornonclearcellrenalcellcarcinomapatientstreatedwithtemsirolimusasfirstlinetherapy |